TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02796053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB08
Description: The TAB08 will be administered intravenously, by infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo to TAB08 will be administered intravenously, by infusion.
Study: NCT01467440

Intervention type: DEVICE
Intervention: Selective Laser Trabeculoplasty
Description: trabeculoplasty with an SLT-Laser to reduce intraocular pressure

Intervention type: DEVICE
Intervention: Selective Laser Trabeculoplasty
Description: trabeculoplasty with an SLT-Laser to reduce intraocular pressure
Study: NCT03928301

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wholetones Music
Description: Participants listened to the Wholetones music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Classical Music
Description: Participants listened to the classical music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
Study: NCT01957397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 1
Description: Coloplast Test 1 is a newly developed 2-piece convex ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 1
Description: Coloplast Test 1 is a newly developed 2-piece convex ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 2
Description: Coloplast Test 2 is a newly developed 2-piece convex ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 2
Description: Coloplast Test 2 is a newly developed 2-piece convex ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 3
Description: Coloplast Test 3 is a newly developed 2-piece convex ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 3
Description: Coloplast Test 3 is a newly developed 2-piece convex ostomy appliance
Study: NCT03687840

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: gait analysis
Description: Computerized gait analysis system was used to 3 times to evaluate the spatio-temporal parameters of gait.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: gait analysis
Description: Computerized gait analysis system was used to 3 times to evaluate the spatio-temporal parameters of gait.
Study: NCT03746392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jumpstart Intervention
Description: The intervention has 4 steps: use electronic medical record (EHR) to identify seriously ill, hospitalized patients with no documentation of a goals-of-care (GOC) discussion during their current admission; the enrolled patient or his/her surrogate completes a survey assessing preferences for discussions about GOC, barriers to having such discussions, and current GOC which is used to create a Jumpstart form designed to prompt and guide a GOC discussion between the patient or surrogate and the clinicians caring for the patient; use natural language processing/machine learning (NLP/ML) approach to identify GOC discussions or advance directives in the EHR that occurred prior to admission and include this information on the Jumpstart form; and, deliver the Jumpstart form to the primary clinician team. The patient or surrogate is also provided with a version of the form.
Study: NCT04007198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EQ001
Description: Itolizumab \[Bmab 600\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EQ001 Placebo
Description: EQ001 Placebo
Study: NCT03251170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will receive :1 mg/Kg ketamine for induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients will receive :2.5 mcg/Kg fentanyl for induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patients will receive 0.05 mg/Kg midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Patients will receive 0.05 mg/Kg midazolam
Study: NCT03825718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC007F
Description: GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.
Study: NCT02756130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00741507

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol drinking
Description: Never drinking of alcohol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol drinking
Description: Mild drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol drinking
Description: Moderate drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol drinking
Description: Severe over drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol drinking
Description: Alcohol-dependent assessed by alcohol use disorders identification test (AUDIT)
Study: NCT02910804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BBN-IRDye800CW

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/NIRF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/NIR fluorescent imaging-guided surgery
Study: NCT00916383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350 mg Donepezil Transdermal Patch
Description: Active and placebo patches will be applied to opposite sides for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350 mg Donepezil Transdermal Patch
Description: Active and placebo patches will be applied to opposite sides for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 350 mg Donepezil Transdermal Patch
Description: Active and placebo patches will be applied to opposite sides for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Active and placebo patches will be applied to opposite sides for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Active and placebo patches will be applied to opposite sides for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Active and placebo patches will be applied to opposite sides for 7 days.
Study: NCT01578629

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin
Description: Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg
Study: NCT03946852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Regional Perfusion
Description: Abdominal Regional Perfusion
Study: NCT03915405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK2455
Description: orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: IV Administration
Study: NCT01994850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Trade name: Adcetris
Study: NCT02473926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical Activity Program Intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Participants in the usual care arm will receive three mailings during the intervention phase.
Study: NCT02321033

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soft drinks
Description: soft drinks with palatinose and maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soft drinks
Description: soft drinks with palatinose and maltodextrin
Study: NCT01689779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100,000 IU cholecalciferol
Description: active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparator drug
Study: NCT04386876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet
Description: Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet
Description: Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH \& Co.-Germany)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet
Description: Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH \& Co.-Germany)
Study: NCT01019837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Focetria (Monovalent MF59-Adjuvanted vaccine)
Description: Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
Study: NCT03656081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled Ambisome®
Description: inhaled liposomal amphotericin B = inhaled LAmB

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inhaled placebo
Description: inhaled isotonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itraconazole
Description: Itraconazole tablet
Study: NCT02004977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improve access to the school breakfast program
Description: Access to the school breakfast program is defined as implementation of a grab-n-go cart outside of the school cafeteria, policy change allowing students to eat in the hallway and marketing of the program. in rural high schools.
Study: NCT04379999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg
Description: No history of colorectal cancer and no colorectal adenomas within 5 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg AND Aspirin 325 mg
Description: History of colorectal cancer and/or history of colorectal adenomas within 5 years.
Study: NCT04014387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant
Description: Suvorexant (Belsomra) is an FDA approved, dual orexin receptor antagonist. It is prescribed for insomnia, reducing time to sleep onset, and to maintain nighttime sleep.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Zolpidem (Ambien) is an FDA approved, Benzodiazepine Receptor agonist that has been extensively studied for the treatment of insomnia in older adults. It acts as a sedative and is typically prescribed to treat insomnia, reducing time to sleep onset, but may not alter the ability to maintain sleep.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo (microcrystalline cellulose) capsules will be used.
Study: NCT03125694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: Sitagliptin arm took sitagliptin 100 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30 mg
Description: Pioglitazone arm took pioglitazone 30 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
Study: NCT03743064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anamorelin HCl
Description: 100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo (administered as matching placebo tablets in the fasted condition)
Study: NCT05055310

Intervention type: DIAGNOSTIC_TEST
Intervention: MicRNAs test
Description: plasma micRNAs concentration

Intervention type: DIAGNOSTIC_TEST
Intervention: MicRNAs test
Description: plasma micRNAs concentration

Intervention type: DIAGNOSTIC_TEST
Intervention: MicRNAs test
Description: plasma micRNAs concentration
Study: NCT01530607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard cyclophosphamide
Description: AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin (Zoladex)
Description: Chemotherapy in Arm 1 plus Goserelin given one week before first chemotherapy dose. Goserelin is given once every 4 weeks during chemo
Study: NCT02073851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriGuard™HDH
Description: TriGuard™HDH Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR)
Study: NCT02603848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: (10mg/kg; maximum 600 mg) every six hours as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.2 mg/ kg morphine suspension (maximum 10mg) every four hours as needed
Study: NCT02387294

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)
Description: vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)
Description: vaccination
Study: NCT03772054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhalation anesthetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous anesthetic agent
Study: NCT02917031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match saxagliptin
Description: 2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
Study: NCT05153213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Finger lengths
Description: Vernier caliper was used to measure finger length

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method
Description: Gillis gauge was used to measure occlusal vertical dimension
Study: NCT03316950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntraGen RF
Description: IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntraGen RF
Description: IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.
Study: NCT01578629

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin
Description: Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo vehicle control
Description: vehicle control compared to Vitamin E TCT pills
Study: NCT02917031

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match sitagliptin
Description: 50 mg or 100 mg, gray capsule
Study: NCT01578629

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo vehicle control
Description: vehicle control compared to Vitamin E TCT pills
Study: NCT03316950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiVA
Description: DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiVA
Description: DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.
Study: NCT02917031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match sitagliptin
Description: 50 mg or 100 mg, gray capsule
Study: NCT04009655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: music selected by musician
Study: NCT03147547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promotional Brochure
Description: Promotional brochure with information about the Triple P Positive Parenting Program and an enrollment form.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Promotional Brochure
Description: Promotional brochure with information about the Triple P Positive Parenting Program and an enrollment form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Testimonial Flyer
Description: Flyer that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teacher Endorsement
Description: Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended the parent attend.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider Engagement Call
Description: This was a manualized, 20-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent problem solve barriers to attendance and develop an action plan to handle common barriers (e.g., scheduling conflicts) as well as set session reminders.
Study: NCT01196546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin/metformin
Study: NCT03684512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Exercise Sessions
Description: Remote exercise sessions delivered over group video conference

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Exercise Sessions
Description: Remote exercise sessions delivered over group video conference

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Support Sessions
Description: Individual education/support/feedback sessions delivered over video chat

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Support Sessions
Description: Individual education/support/feedback sessions delivered over video chat

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facebook Group
Description: Facebook group for parents to provide additional support and education
Study: NCT01135719

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK and PRK
Description: Wavefront-guided versus wavefront-optimized LASIK or PRK.
Study: NCT00279734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus + pnemococcal vaccines alone
Description: 0 mg + vaccines, Single dose, 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept + vaccines
Description: Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept + vaccines
Description: Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept + Vaccines
Description: parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.
Study: NCT03163745

Intervention type: PROCEDURE
Intervention: paracentesis
Description: paracentesis will be done for all patient for ascitic fluid study and ascitic fluid culture
Study: NCT00780078

Intervention type: PROCEDURE
Intervention: extubation
Description: extubation failure in patients intubated orotracheally
Study: NCT03038490

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ABOUND
Description: an oral mixture of arginine, glutamine and beta-hydroxy-beta-methylbutyrate
Study: NCT01894503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S8 Sinus Implant (mometasone furoate, 1350 mcg)
Description: Bioabsorbable sinus implant with 1350 mcg of mometasone furoate released over 90 days
Study: NCT02332824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272
Description: TAK-272 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272
Description: TAK-272 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272
Description: TAK-272 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272
Description: TAK-272 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAK-272 Placebo
Description: TAK-272 placebo-matching tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-272 Placebo
Description: TAK-272 placebo-matching tablets
Study: NCT03316950

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo (DIVA/IntraGen combined)
Description: (DIVA/IntraGen combined) IntraGen RF: IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.~DiVA: DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.
Study: NCT02332824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272 Placebo
Description: TAK-272 placebo-matching tablets
Study: NCT02133976

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mindfulness training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual